Neurogene Inc. (NGNE) Stock

Neurogene Inc. (NGNE) is a Healthcare stock trading at $31.58 (as of 2026-06-18), with a market capitalization of $447.83M and a trailing P/E of -6.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Neurogene Inc. develops genetic medicines focused on neurological diseases. Its pipeline includes an investigational AAV9 gene therapy for Rett syndrome (NGN-401) and a program for neuronal ceroid lipofuscinosis, subtype 5 (NGN-101).

Valuation — source: SEC EDGAR (first-party)

Price	$31.58
Market Cap	$447.83M
P/E Ratio	-6.2
EV / EBITDA	-3.0
Price / Book	1.88
DCF Value (model)	$-78.96
DCF Upside vs Price	-350.0%

Profitability & Growth — source: SEC EDGAR

Revenue (TTM)	$0.00
Return on Equity	-41.5%
Current Ratio	13.08
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	-0.9%
FCF Growth (YoY)	9.7%

Financial Health — source: SEC EDGAR

Altman Z-Score

10.61 (safe)

Valuation vs Sector & Industry

Stock P/E	-6.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-129.8%
vs Industry	-136.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	SAMSARA BIOCAPITAL, LLC ($34.62M)
Institutional Holders Tracked	10

Company

Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Rachel L. McMinn
Employees	107
Country	US
IPO Date	2014-03-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Crescent Biopharma, Inc. (CBIO)
• AC Immune S.A. (ACIU)
• CAMP4 Therapeutics Corporation (CAMP)
• Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
• Allogene Therapeutics, Inc. (ALLO)
• Neumora Therapeutics, Inc. Common Stock (NMRA)
• Aldeyra Therapeutics, Inc. (ALDX)
• Candel Therapeutics, Inc. (CADL)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.